2022 Insights on Cough, Cold and Allergy (Hay Fever) Remedies in the United States: Growth for Cough and Cold Medications Due to the Rise of Respiratory Illnesses - ResearchAndMarkets.com

12 Dec 2022
www.businesswire.com
Drug Approval
DUBLIN--(BUSINESS WIRE)--The "Cough, Cold and Allergy (Hay Fever) Remedies in the US" report has been added to ResearchAndMarkets.com's offering.
'Cough, Cold and Allergy (Hay Fever) Remedies in the US'
Over a year since FDA approval to switch to the OTC market, allergy nasal spray Astepro is now available at retail locations. Astepro is the first and only 24-hour over-the-counter antihistamine nasal spray that is steroid-free.
The 0.15% strength of its active ingredient, azelastine, was the only formulation to be approved for the treatment of rhinitis, and its 0.1% strength formulation for children younger than six remains a prescription product.
The Cough, Cold and Allergy (Hay Fever) Remedies in USA report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2017-2021, allowing you to identify the sectors driving growth. Forecasts to 2026 illustrate how the market is set to change.
Product coverage: Antihistamines/Allergy Remedies (Systemic), Combination - Cough, Cold and Allergy (Hay Fever) Remedies, Cough Remedies, Decongestants, Medicated Confectionery, Paediatric Cough, Cold and Allergy Remedies, Pharyngeal Preparations.
Data coverage: Market sizes (historic and forecasts), company shares, brand shares and distribution data.
Why buy this report?
Get a detailed picture of the Cough, Cold and Allergy (Hay Fever) Remedies market;
Pinpoint growth sectors and identify factors driving change;
Understand the competitive environment, the market's major players and leading brands;
Use five-year forecasts to assess how the market is predicted to develop.
Key Topics Covered:
COUGH, COLDCOLD AND ALLERGY (HAY FEVER) REMEDIES IN THE US
KEY DATA FINDINGS
2022 DEVELOPMENTS
Bayer's Astepro hits the US market following its successful Rx-to-OTC switch
Growth for cough and cold medications due to the rise of respiratory illnesses
Still wary about COVID-19, some consumers are eager to pre-emptively treat symptoms
PROSPECTS AND OPPORTUNITIES
Potential for longer flu seasons could create greater opportunity for year-round sales
Antihistamines/allergy remedies set to perform well over the forecast period
Herbal/natural trend set to expand, especially for paediatric products
CATEGORY DATA
Table 1 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2017-2022
Table 2 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2017-2022
Table 3 NBO Company Shares of Cough, Cold and Allergy (Hay Fever) Remedies: % Value 2018-2022
Table 4 LBN Brand Shares of Cough, Cold and Allergy (Hay Fever) Remedies: % Value 2019-2022
Table 5 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2022-2027
Table 6 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2022-2027
CONSUMER HEALTH IN THE US
Consumer health in 2022: The big picture
2022 key trends
Competitive landscape
Retailing developments
What next for consumer health?
MARKET INDICATORS
Table 7 Consumer Expenditure on Health Goods and Medical Services: Value 2017-2022
Table 8 Life Expectancy at Birth 2017-2022
MARKET DATA
Table 9 Sales of Consumer Health by Category: Value 2017-2022
Table 10 Sales of Consumer Health by Category: % Value Growth 2017-2022
Table 11 NBO Company Shares of Consumer Health: % Value 2018-2022
Table 12 LBN Brand Shares of Consumer Health: % Value 2019-2022
Table 13 Penetration of Private Label in Consumer Health by Category: % Value 2017-2022
Table 14 Distribution of Consumer Health by Format: % Value 2017-2022
Table 15 Distribution of Consumer Health by Format and Category: % Value 2022
Table 16 Forecast Sales of Consumer Health by Category: Value 2022-2027
Table 17 Forecast Sales of Consumer Health by Category: % Value Growth 2022-2027
APPENDIX
OTC registration and classification
Vitamins and dietary supplements registration and classification
Self-medication/self-care and preventive medicine
Summary 1 OTC: Switches 2021-2022
DISCLAIMER
DEFINITIONS
SOURCES
For more information about this report visit https://www.researchandmarkets.com/r/fkdcok
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.